PMID- 21981617
OWN - NLM
STAT- MEDLINE
DCOM- 20120911
LR  - 20181201
IS  - 1540-8183 (Electronic)
IS  - 0896-4327 (Linking)
VI  - 25
IP  - 2
DP  - 2012 Apr
TI  - Bivalirudin used as alternative anticoagulant in carotid artery stenting: a 
      single center observational study.
PG  - 197-202
LID - 10.1111/j.1540-8183.2011.00684.x [doi]
AB  - PURPOSE: To analyze and report the safety and effectiveness of bivalirudin in a 
      large patient population undergoing carotid artery stenting (CAS). METHODS: 
      Between January 2001 and November 2010 extracranial CAS was performed in 272 
      patients in our institution. These patients were stratified according to the 
      anticoagulant used during the CAS procedure into 2 groups (bivalirudin n = 217 
      vs. unfractionated heparin [UFH] n = 55) and analyzed regarding bleeding 
      complications and periprocedural (within 30 days) stroke and myocardial 
      infarction (MI) rates. RESULTS: The combined end-point of death, stroke, and MI 
      occurred in 12 patients (4.4%) with no significant difference between the groups 
      (bivalirudin 4.6% vs. UFH 3.6% P value 0.96). Stroke rates were 1.8% in the 
      bivalirudin and 1.8% in the UFH group (P value 1.00), with 4/5 strokes being 
      nondisabling. Periprocedural MI was observed in 7 patients (2.1%) with no 
      significant differences between the groups (bivalirudin 2.7% vs. UFH 1.8%, P 
      value 0.94). Bleeding complications occurred in 13/272 patients (4.7%) with no 
      significant difference between the groups (bivalirudin 3.6% vs. UFH 9.0%, P value 
      0.15). The first activated clotting time after administration of the 
      anticoagulants was therapeutic in 209/217 (96%) in the bivalirudin group and in 
      30/55 (55%) in the UFH group (P < 0.001). CONCLUSIONS: In this single-center 
      study, bivalirudin was a safe and efficient anticoagulation strategy for CAS and 
      could be considered a therapeutic alternative to UFH.
CI  - (c)2011 Wiley Periodicals, Inc.
FAU - Geisbusch, Philipp
AU  - Geisbusch P
AD  - Baptist Cardiac and Vascular Institute, Division of Vascular and Interventional 
      Radiology, Miami, Florida 33176, USA. philippgeisbuesch@gmx.de
FAU - Katzen, Barry T
AU  - Katzen BT
FAU - Pena, Constantino
AU  - Pena C
FAU - Benenati, James F
AU  - Benenati JF
FAU - Uthoff, Heiko
AU  - Uthoff H
LA  - eng
PT  - Journal Article
DEP - 20111009
PL  - United States
TA  - J Interv Cardiol
JT  - Journal of interventional cardiology
JID - 8907826
RN  - 0 (Antithrombins)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Recombinant Proteins)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antithrombins/*therapeutic use
MH  - Carotid Stenosis/*drug therapy
MH  - Clopidogrel
MH  - Female
MH  - Hirudins
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/*therapeutic use
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Recombinant Proteins/therapeutic use
MH  - Ticlopidine/administration & dosage/analogs & derivatives
EDAT- 2011/10/11 06:00
MHDA- 2012/09/12 06:00
CRDT- 2011/10/11 06:00
PHST- 2011/10/11 06:00 [entrez]
PHST- 2011/10/11 06:00 [pubmed]
PHST- 2012/09/12 06:00 [medline]
AID - 10.1111/j.1540-8183.2011.00684.x [doi]
PST - ppublish
SO  - J Interv Cardiol. 2012 Apr;25(2):197-202. doi: 10.1111/j.1540-8183.2011.00684.x. 
      Epub 2011 Oct 9.